Les maladies concernées, aujourd’hui, par la psychochirurgie
Reference489 articles.
1. Denys D (2006) Pharmacotherapy of obsessive-compulsive disorder and obsessive-compulsive spectrum disorders. Psychiatr Clin North Am 29: 553–84
2. Brody AL, Saxena S, Schwartz JM, et al. (1998) FDG-PET predictors of response to behavioral therapy and pharmacotherapy in obsessive compulsive disorder. Psychiatry Res 84: 1–6
3. Rauch SL, Shin LM, Dougherty DD, et al. (2002) Predictors of fluvoxamine response in contamination-related obsessive compulsive disorder: a PET symptom provocation study. Neuropsychopharmacology 27: 782–91
4. Szeszko PR, Robinson D, Alvir JM, et al. (1999) Orbital frontal and amygdala volume reductions in obsessive-compulsive disorder. Arch Gen Psychiatry 56: 913–9
5. Gilbert AR, Moore GJ, Keshavan MS, et al. (2000) Decrease in thalamic volumes of pediatric patients with obsessive-compulsive disorder who are taking paroxetine. Arch Gen Psychiatry 57: 449–56